CareLit · DOI-Nachweis · Klinische Pädiatrie
A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331
DOI 10.1055/s-0040-1701822
Bibliografische Angaben
Nachweis in CareLit
Autor:innenSK Parsons, Q Pei, K McCarten, S Kessel, A Punnett, TM Horton, TO Henderson, D Hodgson, H Dave, AM Charpentier, FG Keller, KM Kelly
ZeitschriftKlinische Pädiatrie
Ausgabe02/2020
Jahrgang / SeitenJg. 232
Kernaussage aus der Literatur
Abstract-Vorschau
A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331
Zitieren
Zitierempfehlung
SK Parsons, Q Pei, K McCarten, S Kessel, A Punnett, TM Horton, TO Henderson, D Hodgson, H Dave, AM Charpentier, FG Keller, KM Kelly (2020) A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents - Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331. Klinische Pädiatrie, 232 (02). https://doi.org/10.1055/s-0040-1701822
Mit CareLit weiterarbeiten